Press Releases

PDL BioPharma to Announce First Quarter 2011 Financial Results on April 27, 2011 INCLINE VILLAGE, Nev., April 20, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter financial results for the period ended March 31,

PDL BioPharma to Hold Annual Meeting of Stockholders on June 22, 2011 INCLINE VILLAGE, Nev., April 18, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, June 22, 2011 at 10:00 a.m.

PDL BioPharma Announces Conversion Rate Adjustments for 2.00% Convertible Senior Notes Due February 15, 2012 and 2.875% Convertible Senior Notes Due February 15, 2015 INCLINE VILLAGE, Nev., March 8, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced an

PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million INCLINE VILLAGE, Nev., March 7, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the first quarter ending March 31, 2011 of approximately $83 million , as compared

Opposition Appeal Hearing is Terminated --

PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2010 .

Dividend Amount of $0.15 per Share per Quarter --

PDL Settles Litigation and Resolves Other Disputes INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has entered into a definitive settlement agreement with Novartis that resolves all disputes between them.

PDL BioPharma to Present at Upcoming Conferences INCLINE VILLAGE, Nev., Feb. 24, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, is scheduled to present at the following upcoming

PDL BioPharma to Announce Fourth Quarter and Year End 2010 Financial Results on February 28, 2011 INCLINE VILLAGE, Nev., Feb. 22, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will release its fourth quarter and full year financial results

-- All Legal Disputes, Including Those Relating to Synagis(R), Settled --
-- PDL to Pay MedImmune $92.5 Million -

-- All Legal Disputes, Including Those Relating to Cimzia(R), Settled --
-- UCB to Pay PDL US$10 Million --

PDL BioPharma Appoints Caroline Krumel as Vice President of Finance and Thanks Karen Wilson for her Contributions INCLINE VILLAGE, Nev., Jan. 25, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced the appointment of Caroline Krumel , CPA to the position of vice

PDL BioPharma Announces Decisions on Summary Judgment in its Litigation with MedImmune INCLINE VILLAGE, Nev., Jan. 10, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that on January 7, 2011 , the United States District Court for the Northern District of

PDL BioPharma to Present at the 29th Annual JP Morgan Healthcare Conference INCLINE VILLAGE, Nev., Jan. 5, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, is scheduled to present